| Schedule of Segment Information |
The following represents
selected financial information for our segments for the three months ended January 31, 2021 and 2020 and as of January 31, 2021
and October 31, 2020:
| |
|
For the Three Months Ended
January 31, |
|
| |
|
2021 |
|
|
2020 |
|
| Net loss: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(960,736 |
) |
|
$ |
(630,333 |
) |
| Cancer Vaccines |
|
|
(906,336 |
) |
|
|
(195,596 |
) |
| Anti-Viral Therapeutics |
|
|
(480,806 |
) |
|
|
- |
|
| Cancer Diagnostics |
|
|
(8,962 |
) |
|
|
(1,790,646 |
) |
| Patent Licensing |
|
|
124,463 |
|
|
|
- |
|
| Total |
|
$ |
(2,232,377 |
) |
|
$ |
(2,616,575 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
2,745,631 |
|
|
$ |
2,629,869 |
|
| Less non-cash share-based compensation |
|
|
(986,099 |
) |
|
|
(1,021,334 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
1,759,532 |
|
|
$ |
1,608,535 |
|
| |
|
|
|
|
|
|
|
|
| Operating costs and expenses excluding non-cash share based compensation expense: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
557,680 |
|
|
$ |
346,341 |
|
| Cancer Vaccines |
|
|
537,988 |
|
|
|
98,270 |
|
| Anti-Viral Therapeutics |
|
|
270,256 |
|
|
|
- |
|
| Cancer Diagnostics |
|
|
6,432 |
|
|
|
1,163,924 |
|
| Patent Licensing |
|
|
387,176 |
|
|
|
- |
|
| Total |
|
$ |
1,759,532 |
|
|
$ |
1,608,535 |
|
| |
|
January 31,
2021 |
|
|
October 31,
2020 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
5,849,920 |
|
|
$ |
2,988,124 |
|
| Cancer Vaccines |
|
|
5,822,106 |
|
|
|
946,923 |
|
| Anti-Viral Therapeutics |
|
|
2,775,760 |
|
|
|
2,464,361 |
|
| Cancer Diagnostics |
|
|
85,463 |
|
|
|
2,869,529 |
|
| Patent Licensing |
|
|
71,153 |
|
|
|
184,027 |
|
| Total |
|
$ |
14,604,402 |
|
|
$ |
9,452,964 |
|
|